C. Marenghi
University of Milan
PsychiatryCancerInternal medicineRadiologyUrologySurgeryOncologyOdds ratioIntensive care medicinePhysical therapyQualitative researchBiopsyChemotherapyNeutropeniaPTENTolerabilityDiseaseQuality of life (healthcare)Prostate cancerProtocol (science)PopulationGynecologyIn patientVery low riskRe biopsyHealth related quality of lifeRepeat biopsyDoubling timeFamily medicineBreast cancerAnxietyGeneral surgeryClinical psychologyMedicineCohortCoping (psychology)
43Publications
6H-index
201Citations
Publications 45
Newest
#1Lara BellarditaH-Index: 10
#2M.F. AlvisiH-Index: 2
Last. Riccardo ValdagniH-Index: 51
view all 10 authors...
Source
#1Lara BellarditaH-Index: 10
#2Guendalina Graffigna (UCSC: Catholic University of the Sacred Heart)H-Index: 29
Last. Riccardo ValdagniH-Index: 51
view all 9 authors...
Active Surveillance (AS) may represent for selected patients with low risk, potentially indolent prostate cancer (PCa) a viable alternative to radical therapies, thus reducing the risk of over-treatment. Researchers and clinicians emphasized that the choice of AS may be a controversial one as patients have the chance to avoid the side effects of radical therapies but also the burden of living with an untreated PCa. The aim of our study is to focus on the decision-making process leading patients ...
12 CitationsSource
132 Background: Active Surveillance (AS) is offered to prostate cancer (PCa) patients (pts) with very low risk disease, with well defined diagnostic biopsy details. For this reason, in order to standardize diagnostic inclusion criteria, we requested pathologic review before AS enrollment. We here report on second opinion of PCa needle biopsies to determine how often the expert opinion of a uro-pathologist resulted in a different diagnosis, in the group of pts who were proposed for AS. Methods: A...
Source
#1Lara BellarditaH-Index: 10
#2Tiziana RancatiH-Index: 27
Last. Riccardo ValdagniH-Index: 51
view all 10 authors...
2 CitationsSource
#1Maurizio ColecchiaH-Index: 31
#2M.F. AlvisiH-Index: 2
Last. Riccardo ValdagniH-Index: 51
view all 9 authors...
1 CitationsSource
Source
Last. Wataru HabanoH-Index: 23
view all 109 authors...
Source
#1Chiara CataniaH-Index: 21
#2Tommaso De PasH-Index: 35
Last. Franco NolèH-Index: 47
view all 10 authors...
Background: Patients invited to take part in a clinical trial may evoke an archetype on which they may base their decision of adherence to participation, instead of on the study its
39 CitationsSource
Last. Wataru HabanoH-Index: 23
view all 109 authors...
Source
#1C. Marenghi (National Cancer Research Institute)H-Index: 6
#2P. Guglielmini (National Cancer Research Institute)H-Index: 3
Last. Francesco BoccardoH-Index: 45
view all 9 authors...
Aims and background: A retrospective analysis was conducted to evaluate the tolerability as well as the impact of concurrent adjuvant CMF chemotherapy and radiation therapy on total CMF dose and dose intensity. Methods: The medical records of 59 patients who had received conservative or radical surgery for breast cancer were analyzed. All patients had been assigned to 6 cycles of "1,8 CMF" adjuvant chemotherapy and concomitant radiation therapy. Total drug dose and dose intensity were calculated...
1 CitationsSource